Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tiagabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 known ✓ | P30531 | 10/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiagabine SCHEMBL3272861 | 1.00 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4ACYP1A2CYP2D6 | |
| Tiagabine SCHEMBL342814 | 1.00 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4ACYP1A2CYP2D6 | |
| Tiagabine SCHEMBL41860 | 0.99 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL18496408 | 0.99 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL7346237 | 0.99 | SLC6A1 (0.98) | SLC6A1PTGS1PDE4ACYP1A2CYP2D6 | |
| Tiagabine SCHEMBL3958156 | 0.99 | SLC6A1 (0.98) | SLC6A1PTGS1PDE4ACYP1A2CYP2D6 | |
| Tiagabine SCHEMBL17493682 | 0.99 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL5164417 | 0.99 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL1527642 | 0.98 | SLC6A1 (0.98) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| SCHEMBL9773551 | 0.95 | SLC6A1 (0.90) | SLC6A1PTGS1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13611 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | claimed |
| CN-121550436-B | Composition and combination mode | 四川大学华西医院 | 2026-05-12 | — | — | CN | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20260124211-A1 | COMPOSITION CONTAINING LAMOTRIGINE, AND PREPARATION METHOD AND USE THEREOF | SHANGHAI AUCTA PHARMACEUTICALS CO., LTD. (CN) | 2026-05-07 | — | — | US | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-12594256-B2 | A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy | ANAVEX LIFE SCIENCES CORP. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260092932-A1 | METHODS AND COMPOSITIONS FOR THE DETECTION, DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER | THE JOHNSON CENTER FOR CHILD HEALTH AND DEV (US) | 2026-04-02 | — | — | US | claimed |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | claimed |
| CN-1148806-A | Transdermal delivery of anti-epileptic drugs | NOVO NORDISK AS (DK) | 1997-04-30 | — | — | CN | claimed |
| EP-0760656-A1 | TRANSDERMAL DELIVERY OF ANTI-EPILEPTIC DRUGS | NOVO NORDISK A/S (DK) | 1997-03-12 | — | — | EP | claimed |
| EP-0758228-A1 | EFFECTIVE DOSAGE FORM FOR ANTIEPILEPTIC DRUGS | ALZA CORPORATION (US) | 1997-02-19 | — | — | EP | claimed |
| WO-1997002813-A1 | NON-ALLOSTERIC GABAA AGONISTS FOR TREATING SLEEP DISORDERS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1997-01-30 | — | — | WO | claimed |
| WO-1996034606-A1 | PHARMACEUTICAL COMPOSITION CONTAINING TIAGABINE HYDROCHLORIDE AND THE PROCESS FOR ITS PREPARATION | NOVO NORDISK A/S (DK) | 1996-11-07 | — | — | WO | claimed |
| WO-1996015782-A1 | A METHOD FOR TREATING VASCULAR HEADACHES | THE GENERAL HOSPITAL CORPORATION (US) | 1996-05-30 | — | — | WO | claimed |
| WO-1995031976-A1 | TRANSDERMAL DELIVERY OF ANTI-EPILEPTIC DRUGS | NOVO NORDISK A/S (DK) | 1995-11-30 | — | — | WO | claimed |
| WO-1995029665-A1 | EFFECTIVE DOSAGE FORM FOR ANTIEPILEPTIC DRUGS | ALZA CORPORATION (US) | 1995-11-09 | — | — | WO | claimed |
| EP-0579681-A1 | CRYSTALLINE TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-01-26 | — | — | EP | claimed |
| WO-1992017473-A1 | CRYSTALLINE TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1992-10-15 | — | — | WO | claimed |